Literature DB >> 20637769

Impact of a statewide childhood vaccine program in controlling hepatitis A virus infections in Alaska.

Rosalyn J Singleton1, Sarah Hess, Lisa R Bulkow, Louisa Castrodale, Ginger Provo, Brian J McMahon.   

Abstract

Historically, Alaska experienced cyclic hepatitis A virus (HAV) epidemics, and the HAV rate among Alaska Native people was significantly higher than among other racial/ethnic groups. We evaluated the impact of universal childhood vaccination, initiated in 1996, on HAV epidemiology in Alaska by analyzing HAV cases reported to the State of Alaska. HAV incidence in all age groups declined 98.6% from 60.0/100,000 in 1972-1995 to 0.9/100,000 in 2002-2007. The largest decrease (99.9%) was in Alaska Native people, whose incidence (0.3) in 2002-2007 was lower than the overall U.S. 2007 rate (1.0). Among age groups, the decrease (99.8%) among children aged 0-14 years was the largest. Routine childhood vaccination has nearly eliminated HAV infection in Alaska. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20637769     DOI: 10.1016/j.vaccine.2010.06.113

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Physician Knowledge and Attitudes About Hepatitis A and Current Practices Regarding Hepatitis A Vaccination Delivery.

Authors:  Noele P Nelson; Mandy A Allison; Megan C Lindley; Michaela Brtnikova; Lori A Crane; Brenda L Beaty; Laura P Hurley; Allison Kempe
Journal:  Acad Pediatr       Date:  2017-01-09       Impact factor: 3.107

2.  Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children.

Authors:  Gregory A Raczniak; Timothy K Thomas; Lisa R Bulkow; Susan E Negus; Carolyn L Zanis; Michael G Bruce; Philip R Spradling; Eyasu H Teshale; Brian J McMahon
Journal:  Vaccine       Date:  2013-03-05       Impact factor: 3.641

3.  Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series.

Authors:  Gregory A Raczniak; Lisa R Bulkow; Michael G Bruce; Carolyn L Zanis; Richard L Baum; Mary M Snowball; Kathy K Byrd; Umid M Sharapov; Thomas W Hennessy; Brian J McMahon
Journal:  J Infect Dis       Date:  2012-11-29       Impact factor: 5.226

4.  Seroprevalence of hepatitis A virus antibody in a population aged 0-30 years in Shanghai, China: implications for hepatitis A immunization.

Authors:  Y Zhu; Z Yuan; Q Zhao; G Chen; B Xu
Journal:  Epidemiol Infect       Date:  2012-06-12       Impact factor: 4.434

Review 5.  Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review.

Authors:  Anke L Stuurman; Cinzia Marano; Eveline M Bunge; Laurence De Moerlooze; Daniel Shouval
Journal:  Hum Vaccin Immunother       Date:  2016-10-27       Impact factor: 3.452

Review 6.  Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence.

Authors:  Christian Herzog; Koen Van Herck; Pierre Van Damme
Journal:  Hum Vaccin Immunother       Date:  2020-12-16       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.